COVID-19 Update

Combatting Future Viral Threats with Vaccine Advances

The COVID-19 pandemic has led to many changes in how pharmaceutical companies develop vaccines.

What’s Next for COVID-19 Vaccines and Variants?

More technologies and treatments are emerging for COVID-19—along with new variants.

Key Elements for Assay Transfer Success

Partnerships formed during the COVID-19 pandemic have provided a platform for change in assay development and transfers.

FDA Posts Briefing Documents for Vaccine Committee Meeting

December 08, 2020

Pfizer-BioNTech details its case for Emergency Use Authorization for "highly effective" COVID-19 vaccine.

Raw Material Delays Cut Pfizer Vaccine Production

December 04, 2020

A longer-than-expected scale up of raw materials forces Pfizer to cut 2020 vaccine production in half.

J&J Initiates COVID-19 Vaccine Approvals in Canada and Europe

December 03, 2020

Janssen announces rolling submissions for its COVID-19 vaccine with Health Canada and EMA.

Complying with Lab Data Integrity Practices During COVID-19

December 02, 2020

Pharmaceutical laboratories must keep lab data integrity practices in mind in order to properly handle the effects of the COVID-19 pandemic.

Bio/Pharma, People, Perseverance, and Hope

December 02, 2020

After a difficult year, bio/pharma science delivers promising results.

The COVID-19 Vaccine Blind Spot

December 02, 2020

Transparency and open-dialogue are vital to sway the vaccine-hesitant community.

MHRA Grants Emergency Use Authorization for Pfizer and BioNTech’s COVID-19 Vaccine

December 02, 2020

MHRA has granted a temporary authorization for emergency use to Pfizer and BioNTech for the mRNA vaccine against COVID-19.

Moderna Files for FDA EUA for mRNA-1273

December 01, 2020

Moderna has filed for authorization for its COVID-19 vaccine candidate, which has shown high efficacy and safety in a Phase III trial.

Prepping Fill/Finish Systems to Ensure Quality Output

December 01, 2020

A holistic approach to validation and quality assurance is essential.

FDA Grants Fast Track Designation to ARCA biopharma’s Potential COVID-19 Treatment

November 24, 2020

FDA granted fast track designation for AB201, a small recombinant protein that is a potent, selective inhibitor of tissue factor, for the potential treatment of COVID-19.